{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T00:56:56Z","timestamp":1791853016978,"version":"4.3.4"},"reference-count":143,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogenesis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Diffuse large B cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma (NHL), exhibits considerable biological heterogeneity. While its classification has traditionally relied on genetic and transcriptomic features, emerging evidence points to distinct metabolic subtypes that may represent novel therapeutic vulnerabilities. Intriguingly, current chemoimmunotherapy regimens exert profound but non-specific effects on tumour metabolism, inadvertently exploiting metabolic dependencies yet without precision. Novel inhibitors targeting glucose, amino acid, lipid, and mitochondrial metabolism demonstrate selective cytotoxicity in metabolically defined lymphoma subsets. This review investigates how standard therapies exploit DLBCL metabolism and examines heterogeneity across subtypes, and evaluates targeted metabolic therapies. We discuss emerging combination strategies with current therapeutic regimes and immunotherapy. Particular focus is given to the metabolic interactions between tumour cells and immune effectors, including CAR T cells and bispecific antibodies. We highlight the importance of translational research to validate metabolic subtypes through metabolomic profiling, identify predictive biomarkers, and develop rational combinations. Moving beyond empiric therapy towards strategic metabolic targeting offers an opportunity to enhance outcomes for patients with this aggressive and diverse lymphoma.<\/jats:p>","DOI":"10.1038\/s41389-026-00629-x","type":"journal-article","created":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:45:05Z","timestamp":1778874305000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Metabolic vulnerabilities and therapeutic opportunities in diffuse large B-cell lymphoma"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2396-6110","authenticated-orcid":false,"given":"Marie Anne-Catherine","family":"Neumann","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3293-7397","authenticated-orcid":false,"given":"Christian","family":"Frezza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"629_CR1","unstructured":"Young C, Brink R. The unique biology of germinal center B cells. n.d."},{"key":"629_CR2","doi-asserted-by":"crossref","unstructured":"Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. 2000;403.","DOI":"10.1038\/35000501"},{"key":"629_CR3","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy B, Stewart C, Dunford AJ, Kim J, Kamburov A, Redd RA, et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat Med. 2018;24:679\u201390. https:\/\/doi.org\/10.1038\/s41591-018-0016-8.","journal-title":"Nat Med"},{"key":"629_CR4","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/nejmoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396\u2013407. https:\/\/doi.org\/10.1056\/nejmoa1801445.","journal-title":"N Engl J Med"},{"key":"629_CR5","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1182\/blood-2004-07-2947","volume":"105","author":"S Monti","year":"2005","unstructured":"Monti S, Savage KJ, Kutok JL, Feuerhake F, Kurtin P, Mihm M, et al. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood. 2005;105:1851\u201361. https:\/\/doi.org\/10.1182\/blood-2004-07-2947.","journal-title":"Blood"},{"key":"629_CR6","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","volume":"22","author":"P Caro","year":"2012","unstructured":"Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012;22:547\u201360. https:\/\/doi.org\/10.1016\/j.ccr.2012.08.014.","journal-title":"Cancer Cell"},{"key":"629_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-024-01415-3","volume":"16","author":"A Mora","year":"2024","unstructured":"Mora A, Schmidt C, Balderson B, Frezza C, Bod\u00e9n M. SiRCle (Signature Regulatory Clustering) model integration reveals mechanisms of phenotype regulation in renal cancer. Genome Med. 2024;16:144. https:\/\/doi.org\/10.1186\/s13073-024-01415-3.","journal-title":"Genome Med"},{"key":"629_CR8","unstructured":"Vose JM, Bierman PJ, Anderson JR, Kessinger A, Pierson J, Nelson J, et al. Progressive disease after high-dose therapy and autologous transplantation for lymphoid malignancy: clinical course and patient follow-up patient population. n.d."},{"key":"629_CR9","doi-asserted-by":"publisher","unstructured":"Pfreundschuh M, Tr\u00fcmper L, \u00d6sterborg A, Pettengell R, Trneny M, Imrie K, et al. Articles CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group 2006:379. https:\/\/doi.org\/10.1016\/S1470-2045(06).","DOI":"10.1016\/S1470-2045(06)"},{"key":"629_CR10","doi-asserted-by":"publisher","unstructured":"Bock AM, Epperla N. Therapeutic landscape of primary refractory and relapsed diffuse large B-cell lymphoma: Recent advances and emerging therapies. J Hematol Oncol 2025;18. https:\/\/doi.org\/10.1186\/s13045-025-01702-5.","DOI":"10.1186\/s13045-025-01702-5"},{"key":"629_CR11","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1056\/NEJM199304083281404","volume":"328","author":"RI Fisher","year":"1993","unstructured":"Fisher RI, Gaynor ER, Dahlberg S, Oken MM, Grogan TM, Mize EM, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993;328:1002\u20136. https:\/\/doi.org\/10.1056\/NEJM199304083281404.","journal-title":"N Engl J Med"},{"key":"629_CR12","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1158\/2159-8290.CD-18-1393","volume":"9","author":"C Lossos","year":"2019","unstructured":"Lossos C, Liu Y, Kolb KE, Christie AL, Van Scoyk A, Prakadan SM, et al. Mechanisms of lymphoma clearance induced by high-dose alkylating agents. Cancer Discov. 2019;9:944\u201361. https:\/\/doi.org\/10.1158\/2159-8290.CD-18-1393.","journal-title":"Cancer Discov"},{"key":"629_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-31939-9","volume":"8","author":"H Taymaz-Nikerel","year":"2018","unstructured":"Taymaz-Nikerel H, Karabekmez ME, Eraslan S, K\u0131rdar B. Doxorubicin induces an extensive transcriptional and metabolic rewiring in yeast cells. Sci Rep. 2018;8:13672. https:\/\/doi.org\/10.1038\/s41598-018-31939-9.","journal-title":"Sci Rep"},{"key":"629_CR14","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1182\/blood.V60.2.474.474","volume":"60","author":"J White","year":"1982","unstructured":"White J, Rao G. Effects of a microtubule stabilizing agent on the response of platelets to vincristine. Blood. 1982;60:474\u201383. https:\/\/doi.org\/10.1182\/blood.V60.2.474.474.","journal-title":"Blood"},{"key":"629_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-93378-3","volume":"11","author":"E Harno","year":"2021","unstructured":"Harno E, Sefton C, Wray JR, Allen T-J, Davies A, Coll AP, et al. Chronic glucocorticoid treatment induces hepatic lipid accumulation and hyperinsulinaemia in part through actions on AgRP neurons. Sci Rep. 2021;11:13776. https:\/\/doi.org\/10.1038\/s41598-021-93378-3.","journal-title":"Sci Rep"},{"key":"629_CR16","doi-asserted-by":"publisher","first-page":"S45","DOI":"10.1038\/sj.cdd.4401456","volume":"11","author":"S Schmidt","year":"2004","unstructured":"Schmidt S, Rainer J, Ploner C, Presul E, Riml S, Kofler R. Glucocorticoid-induced apoptosis and glucocorticoid resistance: molecular mechanisms and clinical relevance. Cell Death Differ. 2004;11:S45\u201355. https:\/\/doi.org\/10.1038\/sj.cdd.4401456.","journal-title":"Cell Death Differ"},{"key":"629_CR17","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier B, Lepage E, Bri\u00e8re J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235\u201342. https:\/\/doi.org\/10.1056\/NEJMoa011795.","journal-title":"N Engl J Med"},{"key":"629_CR18","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1182\/blood.V128.22.1763.1763","volume":"128","author":"E Vilventhraraja","year":"2016","unstructured":"Vilventhraraja E, Klymenko T, Edelmann J, Gribben J, Ivanov A. Reduction of mitochondrial membrane potential leads to enhancement of type-II CD20-antibody cytotoxicity in diffuse large B-cell lymphoma. Blood. 2016;128:1763\u20131763. https:\/\/doi.org\/10.1182\/blood.V128.22.1763.1763.","journal-title":"Blood"},{"key":"629_CR19","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1182\/blood-2009-08-237537","volume":"115","author":"S Kheirallah","year":"2010","unstructured":"Kheirallah S, Caron P, Gross E, Quillet-Mary A, Bertrand-Michel J, Fourni\u00e9 J-J, et al. Rituximab inhibits B-cell receptor signaling. Blood. 2010;115:985\u201394. https:\/\/doi.org\/10.1182\/blood-2009-08-237537.","journal-title":"Blood"},{"key":"629_CR20","doi-asserted-by":"publisher","first-page":"4020","DOI":"10.18632\/oncotarget.23425","volume":"9","author":"JJ Gu","year":"2018","unstructured":"Gu JJ, Singh A, Xue K, Mavis C, Barth M, Yanamadala V, et al. Up-regulation of hexokinase II contributes to rituximab-chemotherapy resistance and is a clinically relevant target for therapeutic development. Oncotarget. 2018;9:4020\u201333. https:\/\/doi.org\/10.18632\/oncotarget.23425.","journal-title":"Oncotarget"},{"key":"629_CR21","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1056\/nejmoa2115304","volume":"386","author":"H Tilly","year":"2022","unstructured":"Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trn\u011bn\u00fd M, Sharman JP, et al. Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma. N Engl J Med. 2022;386:351\u201363. https:\/\/doi.org\/10.1056\/nejmoa2115304.","journal-title":"N Engl J Med"},{"key":"629_CR22","doi-asserted-by":"publisher","unstructured":"Pal S, Sharma A, Mathew SP, Jaganathan BG. Targeting cancer-specific metabolic pathways for developing novel cancer therapeutics. Front Immunol. 2022;13. https:\/\/doi.org\/10.3389\/fimmu.2022.955476.","DOI":"10.3389\/fimmu.2022.955476"},{"key":"629_CR23","doi-asserted-by":"publisher","unstructured":"Pant K, Kumar A. Editorial: The role of cell metabolism in development, drug resistance, and survival assessment in cancer. Front Mol Biosci. 2025;12. https:\/\/doi.org\/10.3389\/fmolb.2025.1685924.","DOI":"10.3389\/fmolb.2025.1685924"},{"key":"629_CR24","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/j.ccr.2013.11.003","volume":"24","author":"B Chapuy","year":"2013","unstructured":"Chapuy B, McKeown MR, Lin CY, Monti S, Roemer MGM, Qi J, et al. Discovery and characterization of super-enhancer-associated dependencies in diffuse large B cell lymphoma. Cancer Cell. 2013;24:777\u201390. https:\/\/doi.org\/10.1016\/j.ccr.2013.11.003.","journal-title":"Cancer Cell"},{"key":"629_CR25","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/cdd.2016.116","volume":"24","author":"E Norberg","year":"2017","unstructured":"Norberg E, Lako A, Chen P-H, Stanley IA, Zhou F, Ficarro SB, et al. Differential contribution of the mitochondrial translation pathway to the survival of diffuse large B-cell lymphoma subsets. Cell Death Differ. 2017;24:251\u201362. https:\/\/doi.org\/10.1038\/cdd.2016.116.","journal-title":"Cell Death Differ"},{"key":"629_CR26","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1182\/blood-2009-02-205500","volume":"114","author":"D Dornan","year":"2009","unstructured":"Dornan D, Bennett F, Chen Y, Dennis M, Eaton D, Elkins K, et al. Therapeutic potential of an anti-CD79b antibody\u2013drug conjugate, anti\u2013CD79b-vc-MMAE, for the treatment of non-Hodgkin lymphoma. Blood. 2009;114:2721\u20139. https:\/\/doi.org\/10.1182\/blood-2009-02-205500.","journal-title":"Blood"},{"key":"629_CR27","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1111\/ejh.14166","volume":"112","author":"N Yamauchi","year":"2024","unstructured":"Yamauchi N, Maruyama D. Current development of chimeric antigen receptor T-cell therapy for diffuse large B-cell lymphoma and high-grade B-cell lymphoma. Eur J Haematol. 2024;112:662\u201377. https:\/\/doi.org\/10.1111\/ejh.14166.","journal-title":"Eur J Haematol"},{"key":"629_CR28","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1182\/blood.2022016226","volume":"140","author":"A Ali","year":"2022","unstructured":"Ali A, Goy A, Dunleavy K. CAR T-cell therapy in highly aggressive B-cell lymphoma: emerging biological and clinical insights. Blood. 2022;140:1461\u20139. https:\/\/doi.org\/10.1182\/blood.2022016226.","journal-title":"Blood"},{"key":"629_CR29","doi-asserted-by":"publisher","first-page":"5668","DOI":"10.4049\/jimmunol.177.8.5668","volume":"177","author":"A Hombach","year":"2006","unstructured":"Hombach A, K\u00f6hler H, Rappl G, Abken H. Human CD4\u2009+\u2009T cells lyse target cells via granzyme\/perforin upon circumvention of MHC class ii restriction by an antibody-like immunoreceptor. J Immunol. 2006;177:5668\u201375. https:\/\/doi.org\/10.4049\/jimmunol.177.8.5668.","journal-title":"J Immunol"},{"key":"629_CR30","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1038\/s41392-025-02269-w","volume":"10","author":"I Zugasti","year":"2025","unstructured":"Zugasti I, Espinosa-Aroca L, Fidyt K, Mulens-Arias V, Diaz-Beya M, Juan M, et al. CAR-T cell therapy for cancer: current challenges and future directions. Signal Transduct Target Ther. 2025;10:210 https:\/\/doi.org\/10.1038\/s41392-025-02269-w.","journal-title":"Signal Transduct Target Ther"},{"key":"629_CR31","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41586-024-07242-1","volume":"629","author":"JD Chan","year":"2024","unstructured":"Chan JD, Scheffler CM, Munoz I, Sek K, Lee JN, Huang Y-K, et al. FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy. Nature. 2024;629:201\u201310. https:\/\/doi.org\/10.1038\/s41586-024-07242-1.","journal-title":"Nature"},{"key":"629_CR32","doi-asserted-by":"publisher","unstructured":"Li W, Pan X, Chen L, Cui H, Mo S, Pan Y, et al. Cell metabolism-based optimization strategy of CAR-T cell function in cancer therapy. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1186383.","DOI":"10.3389\/fimmu.2023.1186383"},{"key":"629_CR33","doi-asserted-by":"publisher","unstructured":"Nanjireddy PM, Olejniczak SH, Buxbaum NP. Targeting of chimeric antigen receptor T cell metabolism to improve therapeutic outcomes. Front Immunol. 2023;14. https:\/\/doi.org\/10.3389\/fimmu.2023.1121565.","DOI":"10.3389\/fimmu.2023.1121565"},{"key":"629_CR34","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1038\/s41408-024-01193-6","volume":"14","author":"Z Tao","year":"2024","unstructured":"Tao Z, Chyra Z, Kotulov\u00e1 J, Celichowski P, Mih\u00e1lyov\u00e1 J, Charv\u00e1tov\u00e1 S, et al. Impact of T cell characteristics on CAR-T cell therapy in hematological malignancies. Blood Cancer J. 2024;14:213 https:\/\/doi.org\/10.1038\/s41408-024-01193-6.","journal-title":"Blood Cancer J"},{"key":"629_CR35","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-03165-x","volume":"19","author":"M Zhang","year":"2021","unstructured":"Zhang M, Jin X, Sun R, Xiong X, Wang J, Xie D, et al. Optimization of metabolism to improve efficacy during CAR-T cell manufacturing. J Transl Med. 2021;19:499. https:\/\/doi.org\/10.1186\/s12967-021-03165-x.","journal-title":"J Transl Med"},{"key":"629_CR36","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","volume":"7","author":"D Alizadeh","year":"2019","unstructured":"Alizadeh D, Wong RA, Yang X, Wang D, Pecoraro JR, Kuo C-F, et al. IL15 Enhances CAR-T cell antitumor activity by reducing mTORC1 activity and preserving their stem cell memory phenotype. Cancer Immunol Res. 2019;7:759\u201372. https:\/\/doi.org\/10.1158\/2326-6066.CIR-18-0466.","journal-title":"Cancer Immunol Res"},{"key":"629_CR37","doi-asserted-by":"publisher","unstructured":"Battram A, Bachiller M, Urbano-Ispizua \u00c1, Martin-Antonio B. 104 BCMA-targeting CAR-T cells expanded in IL-15 have an improved phenotype for therapeutic use compared to those grown in IL-2 or IL-15\/IL-7. Regular and young investigator award abstracts, BMJ Publishing Group Ltd; 2020, p. A65.1\u2013A65. https:\/\/doi.org\/10.1136\/jitc-2020-SITC2020.0104.","DOI":"10.1136\/jitc-2020-SITC2020.0104"},{"key":"629_CR38","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.cmet.2023.12.010","volume":"36","author":"X Si","year":"2024","unstructured":"Si X, Shao M, Teng X, Huang Y, Meng Y, Wu L, et al. Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation. Cell Metab. 2024;36:176\u2013192.e 10. https:\/\/doi.org\/10.1016\/j.cmet.2023.12.010.","journal-title":"Cell Metab"},{"key":"629_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-52666-y","volume":"15","author":"JA Guerrero","year":"2024","unstructured":"Guerrero JA, Klysz DD, Chen Y, Malipatlolla M, Lone J, Fowler C, et al. GLUT1 overexpression in CAR-T cells induces metabolic reprogramming and enhances potency. Nat Commun. 2024;15:8658. https:\/\/doi.org\/10.1038\/s41467-024-52666-y.","journal-title":"Nat Commun"},{"key":"629_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1038\/s41423-024-01148-8","volume":"21","author":"S Ma","year":"2024","unstructured":"Ma S, Ming Y, Wu J, Cui G. Cellular metabolism regulates the differentiation and function of T-cell subsets. Cell Mol Immunol. 2024;21:419\u201335. https:\/\/doi.org\/10.1038\/s41423-024-01148-8.","journal-title":"Cell Mol Immunol"},{"key":"629_CR41","doi-asserted-by":"publisher","first-page":"115973","DOI":"10.1016\/j.celrep.2025.115973","volume":"44","author":"MS Cook","year":"2025","unstructured":"Cook MS, King E, Flaherty KR, Siddika K, Papa S, Benjamin R, et al. CAR-T cells containing CD28 versus 4-1BB co-stimulatory domains show distinct metabolic profiles in patients. Cell Rep. 2025;44:115973 https:\/\/doi.org\/10.1016\/j.celrep.2025.115973.","journal-title":"Cell Rep"},{"key":"629_CR42","doi-asserted-by":"publisher","unstructured":"Beckermann KE, Hongo R, Ye X, Young K, Carbonell K, Healey DCC, et al. CD28 costimulation drives tumor-infiltrating T cell glycolysis to promote inflammation. JCI Insight 2020;5. https:\/\/doi.org\/10.1172\/jci.insight.138729.","DOI":"10.1172\/jci.insight.138729"},{"key":"629_CR43","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1084\/jem.20171068","volume":"215","author":"AV Menk","year":"2018","unstructured":"Menk AV, Scharping NE, Rivadeneira DB, Calderon MJ, Watson MJ, Dunstane D, et al. 4-1BB costimulation induces T cell mitochondrial function and biogenesis enabling cancer immunotherapeutic responses. J Exp Med. 2018;215:1091\u2013100. https:\/\/doi.org\/10.1084\/jem.20171068.","journal-title":"J Exp Med"},{"key":"629_CR44","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1016\/j.immuni.2016.01.021","volume":"44","author":"OU Kawalekar","year":"2016","unstructured":"Kawalekar OU, O\u2019Connor RS, Fraietta JA, Guo L, McGettigan SE, Posey AD, et al. Distinct signaling of coreceptors regulates specific metabolism pathways and impacts memory development in CAR T cells. Immunity. 2016;44:380\u201390. https:\/\/doi.org\/10.1016\/j.immuni.2016.01.021.","journal-title":"Immunity"},{"key":"629_CR45","doi-asserted-by":"publisher","unstructured":"Minson AG, Dickinson MJ. New bispecific antibodies in diffuse large B-cell lymphoma. Haematologica 2025. https:\/\/doi.org\/10.3324\/haematol.2024.285343.","DOI":"10.3324\/haematol.2024.285343"},{"key":"629_CR46","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1038\/s41416-025-03125-y","volume":"133","author":"G Albayrak","year":"2025","unstructured":"Albayrak G, Wan PK-T, Fisher K, Seymour LW. T cell engagers: expanding horizons in oncology and beyond. Br J Cancer. 2025;133:1241\u20139. https:\/\/doi.org\/10.1038\/s41416-025-03125-y.","journal-title":"Br J Cancer"},{"key":"629_CR47","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-025-02332-6","volume":"10","author":"Z Chao","year":"2025","unstructured":"Chao Z, Mei Q, Yang C, Luo J, Liu P, Peng H, et al. Immunological synapse: structures, molecular mechanisms and therapeutic implications in disease. Signal Transduct Target Ther. 2025;10:254 https:\/\/doi.org\/10.1038\/s41392-025-02332-6.","journal-title":"Signal Transduct Target Ther"},{"key":"629_CR48","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1016\/j.cell.2015.08.016","volume":"162","author":"C-H Chang","year":"2015","unstructured":"Chang C-H, Qiu J, O\u2019Sullivan D, Buck MD, Noguchi T, Curtis JD, et al. Metabolic competition in the tumor microenvironment is a driver of cancer progression. Cell. 2015;162:1229\u201341. https:\/\/doi.org\/10.1016\/j.cell.2015.08.016.","journal-title":"Cell"},{"key":"629_CR49","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","volume":"162","author":"P-C Ho","year":"2015","unstructured":"Ho P-C, Bihuniak JD, Macintyre AN, Staron M, Liu X, Amezquita R, et al. Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses. Cell. 2015;162:1217\u201328. https:\/\/doi.org\/10.1016\/j.cell.2015.08.012.","journal-title":"Cell"},{"key":"629_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/iub.573","volume":"64","author":"AP Halestrap","year":"2012","unstructured":"Halestrap AP. The monocarboxylate transporter family\u2014structure and functional characterization. IUBMB Life. 2012;64:1\u20139. https:\/\/doi.org\/10.1002\/iub.573.","journal-title":"IUBMB Life"},{"key":"629_CR51","doi-asserted-by":"publisher","first-page":"3896","DOI":"10.1093\/emboj\/19.15.3896","volume":"19","author":"P Kirk","year":"2000","unstructured":"Kirk P, Wilson MC, Heddle C, Brown MH, Barclay AN, Halestrap AP. CD147 is tightly associated with lactate transporters MCT1 and MCT4 and facilitates their cell surface expression. EMBO J. 2000;19:3896\u2013904. https:\/\/doi.org\/10.1093\/emboj\/19.15.3896.","journal-title":"EMBO J"},{"key":"629_CR52","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1038\/s41416-019-0717-x","volume":"122","author":"M Beloueche-Babari","year":"2020","unstructured":"Beloueche-Babari M, Casals Galobart T, Delgado-Goni T, Wantuch S, Parkes HG, Tandy D, et al. Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration. Br J Cancer. 2020;122:895\u2013903. https:\/\/doi.org\/10.1038\/s41416-019-0717-x.","journal-title":"Br J Cancer"},{"key":"629_CR53","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.3324\/haematol.2016.163030","volume":"102","author":"RA Noble","year":"2017","unstructured":"Noble RA, Bell N, Blair H, Sikka A, Thomas H, Phillips N, et al. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma. Haematologica. 2017;102:1247\u201357. https:\/\/doi.org\/10.3324\/haematol.2016.163030.","journal-title":"Haematologica"},{"key":"629_CR54","doi-asserted-by":"publisher","first-page":"5913","DOI":"10.1158\/0008-5472.CAN-16-2686","volume":"77","author":"M Beloueche-Babari","year":"2017","unstructured":"Beloueche-Babari M, Wantuch S, Casals Galobart T, Koniordou M, Parkes HG, Arunan V, et al. MCT1 Inhibitor AZD3965 increases mitochondrial metabolism, facilitating combination therapy and noninvasive magnetic resonance spectroscopy. Cancer Res. 2017;77:5913\u201324. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-2686.","journal-title":"Cancer Res"},{"key":"629_CR55","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","volume":"29","author":"S Halford","year":"2023","unstructured":"Halford S, Veal GJ, Wedge SR, Payne GS, Bacon CM, Sloan P, et al. A Phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res. 2023;29:1429\u201339. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2263.","journal-title":"Clin Cancer Res"},{"key":"629_CR56","doi-asserted-by":"publisher","unstructured":"Zhou Y, Lou J, Tian Y, Ding J, Wang X, Tang B. How lactate affects immune strategies in lymphoma. Front Mol Biosci. 2024;11. https:\/\/doi.org\/10.3389\/fmolb.2024.1480884.","DOI":"10.3389\/fmolb.2024.1480884"},{"key":"629_CR57","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1073\/pnas.0914433107","volume":"107","author":"A Le","year":"2010","unstructured":"Le A, Cooper CR, Gouw AM, Dinavahi R, Maitra A, Deck LM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci. 2010;107:2037\u201342. https:\/\/doi.org\/10.1073\/pnas.0914433107.","journal-title":"Proc Natl Acad Sci"},{"key":"629_CR58","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.exphem.2019.09.023","volume":"78","author":"K Nakajima","year":"2019","unstructured":"Nakajima K, Kawashima I, Koshiisi M, Kumagai T, Suzuki M, Suzuki J, et al. Glycolytic enzyme hexokinase II is a putative therapeutic target in B-cell malignant lymphoma. Exp Hematol. 2019;78:46\u201355.e3. https:\/\/doi.org\/10.1016\/j.exphem.2019.09.023.","journal-title":"Exp Hematol"},{"key":"629_CR59","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.1074\/jbc.M109950200","volume":"277","author":"JG Pastorino","year":"2002","unstructured":"Pastorino JG, Shulga N, Hoek JB. Mitochondrial binding of hexokinase II inhibits bax-induced cytochrome c release and apoptosis. J Biol Chem. 2002;277:7610\u20138. https:\/\/doi.org\/10.1074\/jbc.M109950200.","journal-title":"J Biol Chem"},{"key":"629_CR60","doi-asserted-by":"publisher","unstructured":"Zhao H, Xiang G, Shao T, Wang M, Dai W. HK2 contributes to the proliferation, migration, and invasion of diffuse large B-cell lymphoma cells by enhancing the ERK1\/2 signaling pathway. Open Life Sci. 2023;18. https:\/\/doi.org\/10.1515\/biol-2022-0726.","DOI":"10.1515\/biol-2022-0726"},{"key":"629_CR61","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s42255-023-00781-3","volume":"5","author":"D Talwar","year":"2023","unstructured":"Talwar D, Miller CG, Grossmann J, Szyrwiel L, Schwecke T, Demichev V, et al. The GAPDH redox switch safeguards reductive capacity and enables survival of stressed tumour cells. Nat Metab. 2023;5:660\u201376. https:\/\/doi.org\/10.1038\/s42255-023-00781-3.","journal-title":"Nat Metab"},{"key":"629_CR62","doi-asserted-by":"publisher","DOI":"10.1186\/s12870-018-1390-6","volume":"18","author":"M Schneider","year":"2018","unstructured":"Schneider M, Knuesting J, Birkholz O, Heinisch JJ, Scheibe R. Cytosolic GAPDH as a redox-dependent regulator of energy metabolism. BMC Plant Biol. 2018;18:184. https:\/\/doi.org\/10.1186\/s12870-018-1390-6.","journal-title":"BMC Plant Biol"},{"key":"629_CR63","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.cmet.2019.02.002","volume":"29","author":"J Chiche","year":"2019","unstructured":"Chiche J, Reverso-Meinietti J, Mouchotte A, Rubio-Pati\u00f1o C, Mhaidly R, Villa E, et al. GAPDH Expression Predicts the Response to R-CHOP, the Tumor Metabolic Status, and the Response of DLBCL Patients to Metabolic Inhibitors. Cell Metab. 2019;29:1243\u20131257.e 10. https:\/\/doi.org\/10.1016\/j.cmet.2019.02.002.","journal-title":"Cell Metab"},{"key":"629_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0522-0","volume":"9","author":"Y Liu","year":"2018","unstructured":"Liu Y, Cao Y, Pan X, Shi M, Wu Q, Huang T, et al. O-GlcNAc elevation through activation of the hexosamine biosynthetic pathway enhances cancer cell chemoresistance. Cell Death Dis. 2018;9:485. https:\/\/doi.org\/10.1038\/s41419-018-0522-0.","journal-title":"Cell Death Dis"},{"key":"629_CR65","doi-asserted-by":"publisher","first-page":"80599","DOI":"10.18632\/oncotarget.12413","volume":"7","author":"LV Pham","year":"2016","unstructured":"Pham LV, Bryant JL, Mendez R, Chen J, Tamayo AT, Xu-Monette ZY, et al. Targeting the hexosamine biosynthetic pathway and O-linked N-acetylglucosamine cycling for therapeutic and imaging capabilities in diffuse large B-cell lymphoma. Oncotarget. 2016;7:80599\u2013611. https:\/\/doi.org\/10.18632\/oncotarget.12413.","journal-title":"Oncotarget"},{"key":"629_CR66","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s12276-023-00971-9","volume":"55","author":"J Jin","year":"2023","unstructured":"Jin J, Byun J-K, Choi Y-K, Park K-G. Targeting glutamine metabolism as a therapeutic strategy for cancer. Exp Mol Med. 2023;55:706\u201315. https:\/\/doi.org\/10.1038\/s12276-023-00971-9.","journal-title":"Exp Mol Med"},{"key":"629_CR67","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41420-023-01475-1","volume":"9","author":"Y Cai","year":"2023","unstructured":"Cai Y, Lv L, Lu T, Ding M, Yu Z, Chen X, et al. KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis. Cell Death Discov. 2023;9:182 https:\/\/doi.org\/10.1038\/s41420-023-01475-1.","journal-title":"Cell Death Discov"},{"key":"629_CR68","doi-asserted-by":"publisher","first-page":"108523","DOI":"10.1016\/j.bioorg.2025.108523","volume":"161","author":"C Vagaggini","year":"2025","unstructured":"Vagaggini C, D\u2019Ursi P, Poggialini F, Fossa P, Francesconi V, Trombetti G, et al. Deciphering the landscape of allosteric glutaminase 1 inhibitors as anticancer agents. Bioorg Chem. 2025;161:108523 https:\/\/doi.org\/10.1016\/j.bioorg.2025.108523.","journal-title":"Bioorg Chem"},{"key":"629_CR69","doi-asserted-by":"publisher","first-page":"7433","DOI":"10.1182\/bloodadvances.2023010964","volume":"7","author":"B Gomez Solsona","year":"2023","unstructured":"Gomez Solsona B, Horn H, Schmitt A, Xu W, Bucher P, Heinrich A, et al. Inhibition of glutaminase-1 in DLBCL potentiates venetoclax-induced antitumor activity by promoting oxidative stress. Blood Adv. 2023;7:7433\u201344. https:\/\/doi.org\/10.1182\/bloodadvances.2023010964.","journal-title":"Blood Adv"},{"key":"629_CR70","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-27414-1","volume":"12","author":"JL Parker","year":"2021","unstructured":"Parker JL, Deme JC, Kolokouris D, Kuteyi G, Biggin PC, Lea SM, et al. Molecular basis for redox control by the human cystine\/glutamate antiporter system xc\u2212. Nat Commun. 2021;12:7147. https:\/\/doi.org\/10.1038\/s41467-021-27414-1.","journal-title":"Nat Commun"},{"key":"629_CR71","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/s41374-017-0008-1","volume":"98","author":"Y Kinowaki","year":"2018","unstructured":"Kinowaki Y, Kurata M, Ishibashi S, Ikeda M, Tatsuzawa A, Yamamoto M, et al. Glutathione peroxidase 4 overexpression inhibits ROS-induced cell death in diffuse large B-cell lymphoma. Lab Investig. 2018;98:609\u201319. https:\/\/doi.org\/10.1038\/s41374-017-0008-1.","journal-title":"Lab Investig"},{"key":"629_CR72","doi-asserted-by":"crossref","unstructured":"Schmitt A, Xu W, Bucher P, Grimm M, Konantz M, Horn H, et al. Dimethyl fumarate induces ferroptosis and impairs NF-kB\/STAT3 signaling in DLBCL. Blood. 2021;138:871\u2013884.","DOI":"10.1182\/blood.2020009404"},{"key":"629_CR73","doi-asserted-by":"publisher","first-page":"TPS2075","DOI":"10.1200\/JCO.2019.37.15_suppl.TPS2075","volume":"37","author":"SH Kizilbash","year":"2019","unstructured":"Kizilbash SH, McBrayer S, Port J, Reid JM, Lanza I, Allred JB, et al. A phase Ib trial of CB-839 (telaglenastat) in combination with radiation therapy and temozolomide in patients with IDH-mutated diffuse astrocytoma and anaplastic astrocytoma (NCT03528642). J Clin Oncol. 2019;37:TPS2075\u2013TPS2075. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.TPS2075.","journal-title":"J Clin Oncol"},{"key":"629_CR74","doi-asserted-by":"publisher","unstructured":"Timofeeva N, Ayres ML, Baran N, Santiago-O\u2019Farrill JM, Bildik G, Lu Z, et al. Preclinical investigations of the efficacy of the glutaminase inhibitor CB-839 alone and in combinations in chronic lymphocytic leukemia. Front Oncol. 2023;13. https:\/\/doi.org\/10.3389\/fonc.2023.1161254.","DOI":"10.3389\/fonc.2023.1161254"},{"key":"629_CR75","doi-asserted-by":"publisher","first-page":"3338","DOI":"10.62347\/XWSP9750","volume":"15","author":"L Yuan","year":"2025","unstructured":"Yuan L. Optimization of CAR-T therapy based on metabolic remodeling of the tumor immune microenvironment in diffuse large B-cell lymphoma. Am J Cancer Res. 2025;15:3338\u201358. https:\/\/doi.org\/10.62347\/XWSP9750.","journal-title":"Am J Cancer Res"},{"key":"629_CR76","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-017-04626-4","volume":"7","author":"J-G Ren","year":"2017","unstructured":"Ren J-G, Seth P, Ye H, Guo K, Hanai J, Husain Z, et al. Citrate suppresses tumor growth in multiple models through inhibition of glycolysis, the tricarboxylic acid cycle and the IGF-1R pathway. Sci Rep. 2017;7:4537. https:\/\/doi.org\/10.1038\/s41598-017-04626-4.","journal-title":"Sci Rep"},{"key":"629_CR77","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1007\/s13238-017-0451-1","volume":"9","author":"NM Anderson","year":"2018","unstructured":"Anderson NM, Mucka P, Kern JG, Feng H. The emerging role and targetability of the TCA cycle in cancer metabolism. Protein Cell. 2018;9:216\u201337. https:\/\/doi.org\/10.1007\/s13238-017-0451-1.","journal-title":"Protein Cell"},{"key":"629_CR78","doi-asserted-by":"publisher","first-page":"665","DOI":"10.4155\/fmc-2021-0341","volume":"14","author":"SA Patil","year":"2022","unstructured":"Patil SA, Mayor JA, Kaplan RS. Citrate transporter inhibitors: possible new anticancer agents. Future Med Chem. 2022;14:665\u201379. https:\/\/doi.org\/10.4155\/fmc-2021-0341.","journal-title":"Future Med Chem"},{"key":"629_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-33138-7","volume":"13","author":"R Peeters","year":"2022","unstructured":"Peeters R, Cuenca-Escalona J, Zaal EA, Hoekstra AT, Balvert ACG, Vidal-Manrique M, et al. Fatty acid metabolism in aggressive B-cell lymphoma is inhibited by tetraspanin CD37. Nat Commun. 2022;13:5371. https:\/\/doi.org\/10.1038\/s41467-022-33138-7.","journal-title":"Nat Commun"},{"key":"629_CR80","doi-asserted-by":"publisher","unstructured":"Wei P, Bott AJ, Cluntun AA, Morgan JT, Cunningham CN, Schell JC, et al. Mitochondrial pyruvate supports lymphoma proliferation by fueling a glutamate pyruvate transaminase 2-dependent glutaminolysis pathway. Sci Adv. 2022;8. https:\/\/doi.org\/10.1126\/sciadv.abq0117.","DOI":"10.1126\/sciadv.abq0117"},{"key":"629_CR81","doi-asserted-by":"publisher","unstructured":"Fei F, Zheng M, Xu Z, Sun R, Chen X, Cao B, et al. Plasma metabolites forecast occurrence and prognosis for patients with diffuse large B-cell lymphoma. Front Oncol. 2022;12. https:\/\/doi.org\/10.3389\/fonc.2022.894891.","DOI":"10.3389\/fonc.2022.894891"},{"key":"629_CR82","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1038\/s41388-021-02056-1","volume":"41","author":"G Alzial","year":"2022","unstructured":"Alzial G, Renoult O, Paris F, Gratas C, Clavreul A, Pecqueur C. Wild-type isocitrate dehydrogenase under the spotlight in glioblastoma. Oncogene. 2022;41:613\u201321. https:\/\/doi.org\/10.1038\/s41388-021-02056-1.","journal-title":"Oncogene"},{"key":"629_CR83","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1038\/s41388-017-0077-z","volume":"37","author":"RJ Molenaar","year":"2018","unstructured":"Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and mutated IDH1\/2 enzymes and therapy responses. Oncogene. 2018;37:1949\u201360. https:\/\/doi.org\/10.1038\/s41388-017-0077-z.","journal-title":"Oncogene"},{"key":"629_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04494-9","volume":"21","author":"H Shi","year":"2023","unstructured":"Shi H, Pan Y, Xiang G, Wang M, Huang Y, He L, et al. A novel NET-related gene signature for predicting DLBCL prognosis. J Transl Med. 2023;21:630. https:\/\/doi.org\/10.1186\/s12967-023-04494-9.","journal-title":"J Transl Med"},{"key":"629_CR85","doi-asserted-by":"publisher","unstructured":"Mi W, Xue Y, Yan H, Zhang Y, Cai X, Zhang S, et al. \u03b1-Ketoglutarate dictates AMPK protein synthesis for energy sensing in human cancers. Nat Chem Biol. 2025. https:\/\/doi.org\/10.1038\/s41589-025-02013-z.","DOI":"10.1038\/s41589-025-02013-z"},{"key":"629_CR86","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.semcdb.2019.05.031","volume":"98","author":"H Abla","year":"2020","unstructured":"Abla H, Sollazzo M, Gasparre G, Iommarini L, Porcelli AM. The multifaceted contribution of \u03b1-ketoglutarate to tumor progression: an opportunity to exploit?. Semin Cell Dev Biol. 2020;98:26\u201333. https:\/\/doi.org\/10.1016\/j.semcdb.2019.05.031.","journal-title":"Semin Cell Dev Biol"},{"key":"629_CR87","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/s41420-023-01475-1","volume":"9","author":"Y Cai","year":"2023","unstructured":"Cai Y, Lv L, Lu T, Ding M, Yu Z, Chen X, et al. \u03b1-KG inhibits tumor growth of diffuse large B-cell lymphoma by inducing ROS and TP53-mediated ferroptosis. Cell Death Discov. 2023;9:182 https:\/\/doi.org\/10.1038\/s41420-023-01475-1.","journal-title":"Cell Death Discov"},{"key":"629_CR88","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/s41420-025-02826-w","volume":"11","author":"A Langpape","year":"2025","unstructured":"Langpape A, Bonasera D, Stroh J, Reese M, Cartolano M, Liccardi G, et al. Redox destabilization by ibrutinib promotes ferroptosis in diffuse large B-cell lymphoma (DLBCL). Cell Death Discov. 2025;11:495 https:\/\/doi.org\/10.1038\/s41420-025-02826-w.","journal-title":"Cell Death Discov"},{"key":"629_CR89","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.canlet.2019.07.001","volume":"461","author":"J Li","year":"2019","unstructured":"Li J, Liang N, Long X, Zhao J, Yang J, Du X, et al. SDHC-related deficiency of SDH complex activity promotes growth and metastasis of hepatocellular carcinoma via ROS\/NF\u03baB signaling. Cancer Lett. 2019;461:44\u201355. https:\/\/doi.org\/10.1016\/j.canlet.2019.07.001.","journal-title":"Cancer Lett"},{"key":"629_CR90","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s10565-025-10022-w","volume":"41","author":"J Wang","year":"2025","unstructured":"Wang J, Yuan T, Yang B, He Q, Zhu H. SDH defective cancers: molecular mechanisms and treatment strategies. Cell Biol Toxicol. 2025;41:74 https:\/\/doi.org\/10.1007\/s10565-025-10022-w.","journal-title":"Cell Biol Toxicol"},{"key":"629_CR91","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1126\/science.aan4665","volume":"360","author":"MD Kornberg","year":"2018","unstructured":"Kornberg MD, Bhargava P, Kim PM, Putluri V, Snowman AM, Putluri N, et al. Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity. Science. 2018;360:449\u201353. https:\/\/doi.org\/10.1126\/science.aan4665.","journal-title":"Science"},{"key":"629_CR92","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s42003-023-05443-4","volume":"6","author":"MC Oca\u00f1a","year":"2023","unstructured":"Oca\u00f1a MC, Bernal M, Yang C, Caro C, Dom\u00ednguez A, Vu HS, et al. New insights in the targets of action of dimethyl fumarate in endothelial cells: effects on energetic metabolism and serine synthesis in vitro and in vivo. Commun Biol. 2023;6:1084 https:\/\/doi.org\/10.1038\/s42003-023-05443-4.","journal-title":"Commun Biol"},{"key":"629_CR93","doi-asserted-by":"publisher","unstructured":"Valcarcel-Jimenez L, Frezza C. Fumarate hydratase (FH) and cancer: a paradigm of oncometabolism. Br J Cancer. 2023. https:\/\/doi.org\/10.1038\/s41416-023-02412-w.","DOI":"10.1038\/s41416-023-02412-w"},{"key":"629_CR94","doi-asserted-by":"publisher","unstructured":"Peace CG, O\u2019Carroll SM, O\u2019Neill LAJ. Fumarate hydratase as a metabolic regulator of immunity. Trends Cell Biol. 2023. https:\/\/doi.org\/10.1016\/j.tcb.2023.10.005.","DOI":"10.1016\/j.tcb.2023.10.005"},{"key":"629_CR95","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-025-08040-x","volume":"16","author":"S Kawaguchi","year":"2025","unstructured":"Kawaguchi S, Sato K, Izawa J, Takayama N, Hayakawa H, Tominaga K, et al. The combination of venetoclax with dimethyl fumarate synergistically induces apoptosis in AML cells by disrupting mitochondrial integrity through ROS accumulation. Cell Death Dis. 2025;16:750. https:\/\/doi.org\/10.1038\/s41419-025-08040-x.","journal-title":"Cell Death Dis"},{"key":"629_CR96","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41573-021-00339-6","volume":"21","author":"ZE Stine","year":"2022","unstructured":"Stine ZE, Schug ZT, Salvino JM, Dang CV. Targeting cancer metabolism in the era of precision oncology. Nat Rev Drug Discov. 2022;21:141\u201362. https:\/\/doi.org\/10.1038\/s41573-021-00339-6.","journal-title":"Nat Rev Drug Discov"},{"key":"629_CR97","doi-asserted-by":"publisher","first-page":"3014","DOI":"10.1200\/JCO.2019.37.15_suppl.3014","volume":"37","author":"TA Yap","year":"2019","unstructured":"Yap TA, Rodon Ahnert J, Piha-Paul SA, Fu S, Janku F, Karp DD, et al. Phase I trial of IACS-010759 (IACS), a potent, selective inhibitor of complex I of the mitochondrial electron transport chain, in patients (pts) with advanced solid tumors. J Clin Oncol. 2019;37:3014\u20133014. https:\/\/doi.org\/10.1200\/JCO.2019.37.15_suppl.3014.","journal-title":"J Clin Oncol"},{"key":"629_CR98","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1002\/1878-0261.13583","volume":"18","author":"M Pujalte-Martin","year":"2024","unstructured":"Pujalte-Martin M, Bela\u00efd A, Bost S, Kahi M, Peraldi P, Rouleau M, et al. Targeting cancer and immune cell metabolism with the complex I inhibitors metformin and IACS-010759. Mol Oncol. 2024;18:1719\u201338. https:\/\/doi.org\/10.1002\/1878-0261.13583.","journal-title":"Mol Oncol"},{"key":"629_CR99","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1007\/s10637-022-01277-9","volume":"40","author":"F Janku","year":"2022","unstructured":"Janku F, Beom S-H, Moon YW, Kim TW, Shin YG, Yim D-S, et al. First-in-human study of IM156, a novel potent biguanide oxidative phosphorylation (OXPHOS) inhibitor, in patients with advanced solid tumors. Investig N Drugs. 2022;40:1001\u201310. https:\/\/doi.org\/10.1007\/s10637-022-01277-9.","journal-title":"Investig N Drugs"},{"key":"629_CR100","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1038\/s41416-022-01848-w","volume":"127","author":"RA Noble","year":"2022","unstructured":"Noble RA, Thomas H, Zhao Y, Herendi L, Howarth R, Dragoni I, et al. Simultaneous targeting of glycolysis and oxidative phosphorylation as a therapeutic strategy to treat diffuse large B-cell lymphoma. Br J Cancer. 2022;127:937\u201347. https:\/\/doi.org\/10.1038\/s41416-022-01848-w.","journal-title":"Br J Cancer"},{"key":"629_CR101","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1038\/s41375-021-01502-z","volume":"36","author":"F Seyfried","year":"2022","unstructured":"Seyfried F, Stirnwei\u00df FU, Niedermayer A, Enzenm\u00fcller S, H\u00f6rl RL, M\u00fcnch V, et al. Synergistic activity of combined inhibition of anti-apoptotic molecules in B-cell precursor ALL. Leukemia. 2022;36:901\u201312. https:\/\/doi.org\/10.1038\/s41375-021-01502-z.","journal-title":"Leukemia"},{"key":"629_CR102","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/1878-0261.13115","volume":"16","author":"G Donati","year":"2022","unstructured":"Donati G, Rav\u00e0 M, Filipuzzi M, Nicoli P, Cassina L, Verrecchia A, et al. Targeting mitochondrial respiration and the BCL2 family in high-grade MYC-associated B-cell lymphoma. Mol Oncol. 2022;16:1132\u201352. https:\/\/doi.org\/10.1002\/1878-0261.13115.","journal-title":"Mol Oncol"},{"key":"629_CR103","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1182\/blood.2023020142","volume":"142","author":"Y Liu","year":"2023","unstructured":"Liu Y, Kimpara S, Hoang NM, Daenthanasanmak A, Li Y, Lu L, et al. EGR1-mediated metabolic reprogramming to oxidative phosphorylation contributes to ibrutinib resistance in B-cell lymphoma. Blood. 2023;142:1879\u201394. https:\/\/doi.org\/10.1182\/blood.2023020142.","journal-title":"Blood"},{"key":"629_CR104","doi-asserted-by":"publisher","first-page":"101484","DOI":"10.1016\/j.xcrm.2024.101484","volume":"5","author":"N-M Hoang","year":"2024","unstructured":"Hoang N-M, Liu Y, Bates PD, Heaton AR, Lopez AF, Liu P, et al. Targeting DNMT3A-mediated oxidative phosphorylation to overcome ibrutinib resistance in mantle cell lymphoma. Cell Rep Med. 2024;5:101484 https:\/\/doi.org\/10.1016\/j.xcrm.2024.101484.","journal-title":"Cell Rep Med"},{"key":"629_CR105","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1182\/blood.V126.23.1284.1284","volume":"126","author":"R Dashnamoorthy","year":"2015","unstructured":"Dashnamoorthy R, Beheshti A, Abermil N, Lansigan F, Kinlaw W, Gartenhaus R, et al. Lipid addiction of diffuse large B-cell lymphoma (DLBCL): fatty acid synthase (FASN) and PI3K dependent cell death identifies a novel therapeutic paradigm. Blood. 2015;126:1284\u20131284. https:\/\/doi.org\/10.1182\/blood.V126.23.1284.1284.","journal-title":"Blood"},{"key":"629_CR106","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02848-9","volume":"19","author":"S Mao","year":"2021","unstructured":"Mao S, Ling Q, Pan J, Li F, Huang S, Ye W, et al. Inhibition of CPT1a as a prognostic marker can synergistically enhance the antileukemic activity of ABT199. J Transl Med. 2021;19:181. https:\/\/doi.org\/10.1186\/s12967-021-02848-9.","journal-title":"J Transl Med"},{"key":"629_CR107","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.3324\/haematol.2022.281420","volume":"108","author":"AS Gerdtsson","year":"2022","unstructured":"Gerdtsson AS, Matos Rodrigues J, de, Eskelund CW, Husby S, Gr\u00f8nb\u00e6k K, R\u00e4ty R, et al. Overexpression of the key metabolic protein CPT1A defines mantle cell lymphoma patients with poor response to standard high-dose chemotherapy independent of MIPI and complement established high risk factors. Haematologica. 2022;108:1092\u2013104. https:\/\/doi.org\/10.3324\/haematol.2022.281420.","journal-title":"Haematologica"},{"key":"629_CR108","doi-asserted-by":"publisher","first-page":"831","DOI":"10.1158\/1538-7445.AM2025-831","volume":"85","author":"S Steinlein","year":"2025","unstructured":"Steinlein S, Horn H, Attwood E, Staiger AM, Kurz KS, Rosenwald A, et al. Abstract 831: CPT1A inhibition sensitizes diffuse large B-cell lymphoma to venetoclax treatment. Cancer Res. 2025;85:831\u2013831. https:\/\/doi.org\/10.1158\/1538-7445.AM2025-831.","journal-title":"Cancer Res"},{"key":"629_CR109","doi-asserted-by":"publisher","first-page":"e531","DOI":"10.3324\/haematol.2017.175414","volume":"103","author":"E Gugiatti","year":"2018","unstructured":"Gugiatti E, Tenca C, Ravera S, Fabbi M, Ghiotto F, Mazzarello AN, et al. A reversible carnitine palmitoyltransferase (CPT1) inhibitor offsets the proliferation of chronic lymphocytic leukemia cells. Haematologica. 2018;103:e531\u20136. https:\/\/doi.org\/10.3324\/haematol.2017.175414.","journal-title":"Haematologica"},{"key":"629_CR110","doi-asserted-by":"publisher","first-page":"707","DOI":"10.3390\/biomedicines13030707","volume":"13","author":"A Montagne","year":"2025","unstructured":"Montagne A, Kotta K, Kielbassa-Elkadi K, Martins I, Martinez-Climent J\u00c1, Kroemer G, et al. Fatty acid metabolism provides an essential survival signal in OxPhos and BCR DLBCL cells. Biomedicines. 2025;13:707 https:\/\/doi.org\/10.3390\/biomedicines13030707.","journal-title":"Biomedicines"},{"key":"629_CR111","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1042\/CS20060307","volume":"113","author":"CJF Holubarsch","year":"2007","unstructured":"Holubarsch CJF, Rohrbach M, Karrasch M, Boehm E, Polonski L, Ponikowski P, et al. A double-blind randomized multicentre clinical trial to evaluate the efficacy and safety of two doses of etomoxir in comparison with placebo in patients with moderate congestive heart failure: the ERGO (etomoxir for the recovery of glucose oxidation) study. Clin Sci. 2007;113:205\u201312. https:\/\/doi.org\/10.1042\/CS20060307.","journal-title":"Clin Sci"},{"key":"629_CR112","doi-asserted-by":"publisher","first-page":"101288","DOI":"10.1016\/j.plipres.2024.101288","volume":"95","author":"J Lee","year":"2024","unstructured":"Lee J, Mani A, Shin M-J, Krauss RM. Leveraging altered lipid metabolism in treating B cell malignancies. Prog Lipid Res. 2024;95:101288 https:\/\/doi.org\/10.1016\/j.plipres.2024.101288.","journal-title":"Prog Lipid Res"},{"key":"629_CR113","doi-asserted-by":"publisher","unstructured":"Zhong X, Zhang W, Zhang W, Yu N, Li W, Song X. FASN contributes to ADM resistance of diffuse large B-cell lymphoma by inhibiting ferroptosis via nf-\u03baB\/STAT3\/GPX4 axis. Cancer Biol Ther. 2024;25. https:\/\/doi.org\/10.1080\/15384047.2024.2403197.","DOI":"10.1080\/15384047.2024.2403197"},{"key":"629_CR114","doi-asserted-by":"publisher","first-page":"2711","DOI":"10.1182\/blood.V120.21.2711.2711","volume":"120","author":"R Dashnamoorthy","year":"2012","unstructured":"Dashnamoorthy R, Lansigan F, Davis WL, Kuemmerle N, Kinlaw WB, Evens AM. Fatty acid metabolism in diffuse large B-cell lymphoma (DLBCL): interaction with oncogenic cell signaling pathways and the identification of a novel treatment paradigm. Blood. 2012;120:2711\u20132711. https:\/\/doi.org\/10.1182\/blood.V120.21.2711.2711.","journal-title":"Blood"},{"key":"629_CR115","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1182\/blood.2022019274","volume":"142","author":"A Schmitt","year":"2023","unstructured":"Schmitt A, Grimm M, Kreienkamp N, Junge H, Labisch J, Schuhknecht L, et al. BRD4 inhibition sensitizes diffuse large B-cell lymphoma cells to ferroptosis. Blood. 2023;142:1143\u201355. https:\/\/doi.org\/10.1182\/blood.2022019274.","journal-title":"Blood"},{"key":"629_CR116","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.semcdb.2019.05.002","volume":"98","author":"C Schmidt","year":"2020","unstructured":"Schmidt C, Sciacovelli M, Frezza C. Fumarate hydratase in cancer: a multifaceted tumour suppressor. Semin Cell Dev Biol. 2020;98:15\u201325. https:\/\/doi.org\/10.1016\/j.semcdb.2019.05.002.","journal-title":"Semin Cell Dev Biol"},{"key":"629_CR117","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/molecules29020531","volume":"29","author":"X Zhou","year":"2024","unstructured":"Zhou X, Su M, Lu J, Li D, Niu X, Wang Y. CD36: the bridge between lipids and tumors. Molecules. 2024;29:531 https:\/\/doi.org\/10.3390\/molecules29020531.","journal-title":"Molecules"},{"key":"629_CR118","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s12308-012-0166-4","volume":"6","author":"OV Danilova","year":"2013","unstructured":"Danilova OV, Dumont LJ, Levy NB, Lansigan F, Kinlaw WB, Danilov AV, et al. FASN and CD36 predict survival in rituximab-treated diffuse large B-cell lymphoma. J Hematop. 2013;6:11\u20138. https:\/\/doi.org\/10.1007\/s12308-012-0166-4.","journal-title":"J Hematop"},{"key":"629_CR119","doi-asserted-by":"publisher","unstructured":"Yang S, Damiano MG, Zhang H, Tripathy S, Luthi AJ, Rink JS, et al. Biomimetic, synthetic HDL nanostructures for lymphoma. Proc Natl Acad Sci. 2013;110:2511\u20136. https:\/\/doi.org\/10.1073\/pnas.1213657110.","DOI":"10.1073\/pnas.1213657110"},{"key":"629_CR120","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1021\/acs.molpharmaceut.7b00710","volume":"14","author":"JS Rink","year":"2017","unstructured":"Rink JS, Yang S, Cen O, Taxter T, McMahon KM, Misener S, et al. Rational targeting of cellular cholesterol in diffuse large B-cell lymphoma (DLBCL) enabled by functional lipoprotein nanoparticles: a therapeutic strategy dependent on cell of origin. Mol Pharm. 2017;14:4042\u201351. https:\/\/doi.org\/10.1021\/acs.molpharmaceut.7b00710.","journal-title":"Mol Pharm"},{"key":"629_CR121","doi-asserted-by":"publisher","first-page":"100295","DOI":"10.1016\/j.medntd.2024.100295","volume":"22","author":"Z Liu","year":"2024","unstructured":"Liu Z, Wu C, Yao Z, Wang Y, Yu Z, Yu J. Targeting lipid metabolism overcomes BTK inhibitor resistance in diffuse large B-cell lymphoma. Med Nov Technol Devices. 2024;22:100295 https:\/\/doi.org\/10.1016\/j.medntd.2024.100295.","journal-title":"Med Nov Technol Devices"},{"key":"629_CR122","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-47305-2","volume":"9","author":"B Sharif-Askari","year":"2019","unstructured":"Sharif-Askari B, Doyon D, Paliouras M, Aloyz R. Bruton\u2019s tyrosine kinase is at the crossroads of metabolic adaptation in primary malignant human lymphocytes. Sci Rep. 2019;9:11069. https:\/\/doi.org\/10.1038\/s41598-019-47305-2.","journal-title":"Sci Rep"},{"key":"629_CR123","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1194\/jlr.TR120000658","volume":"61","author":"D Sviridov","year":"2020","unstructured":"Sviridov D, Mukhamedova N, Miller YI. Lipid rafts as a therapeutic target. J Lipid Res. 2020;61:687\u201395. https:\/\/doi.org\/10.1194\/jlr.TR120000658.","journal-title":"J Lipid Res"},{"key":"629_CR124","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-45721-z","volume":"13","author":"M Deng","year":"2023","unstructured":"Deng M, Tan J, Fan Z, Pham LV, Zhu F, Fang X, et al. The synergy of the XPO1 inhibitors combined with the BET inhibitor INCB057643 in high-grade B-cell lymphoma via downregulation of MYC expression. Sci Rep. 2023;13:18554. https:\/\/doi.org\/10.1038\/s41598-023-45721-z.","journal-title":"Sci Rep"},{"key":"629_CR125","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1158\/1535-7163.MCT-17-0789-ATR","volume":"17","author":"M Ming","year":"2018","unstructured":"Ming M, Wu W, Xie B, Sukhanova M, Wang W, Kadri S, et al. XPO1 inhibitor selinexor overcomes intrinsic ibrutinib resistance in mantle cell lymphoma via nuclear retention of I\u03baB. Mol Cancer Ther. 2018;17:2564\u201374. https:\/\/doi.org\/10.1158\/1535-7163.MCT-17-0789-ATR.","journal-title":"Mol Cancer Ther"},{"key":"629_CR126","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.clml.2021.12.016","volume":"22","author":"M Schuster","year":"2022","unstructured":"Schuster M, Zijlstra J, Casasnovas R-O, Vermaat JSP, Kalakonda N, Goy A, et al. Effect of prior therapy and disease refractoriness on the efficacy and safety of oral selinexor in patients with diffuse large B-cell lymphoma (DLBCL): a post-hoc analysis of the SADAL study. Clin Lymphoma Myeloma Leuk. 2022;22:483\u201394. https:\/\/doi.org\/10.1016\/j.clml.2021.12.016.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"629_CR127","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41568-022-00535-5","volume":"23","author":"FJ Groelly","year":"2023","unstructured":"Groelly FJ, Fawkes M, Dagg RA, Blackford AN, Tarsounas M, Targeting DNA. damage response pathways in cancer. Nat Rev Cancer. 2023;23:78\u201394. https:\/\/doi.org\/10.1038\/s41568-022-00535-5.","journal-title":"Nat Rev Cancer"},{"key":"629_CR128","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S1470-2045(14)71135-0","volume":"16","author":"AM Oza","year":"2015","unstructured":"Oza AM, Cibula D, Benzaquen AO, Poole C, Mathijssen RHJ, Sonke GS, et al. Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial. Lancet Oncol. 2015;16:87\u201397. https:\/\/doi.org\/10.1016\/S1470-2045(14)71135-0.","journal-title":"Lancet Oncol"},{"key":"629_CR129","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","volume":"36","author":"S Parvin","year":"2019","unstructured":"Parvin S, Ramirez-Labrada A, Aumann S, Lu X, Weich N, Santiago G, et al. LMO2 confers synthetic lethality to PARP inhibition in DLBCL. Cancer Cell. 2019;36:237\u2013249.e6. https:\/\/doi.org\/10.1016\/j.ccell.2019.07.007.","journal-title":"Cancer Cell"},{"key":"629_CR130","doi-asserted-by":"publisher","unstructured":"Ana\u00efs A, Ivan N, Ashaina V, Pauline M, No\u00e9mie D, Rachel P, et al. L-asparaginase treatment induces a tumor metabolic plasticity and reveals a vulnerability to PARP1\/2 inhibitor Olaparib, in B-cell lymphomas 2025. https:\/\/doi.org\/10.1101\/2025.10.24.683536.","DOI":"10.1101\/2025.10.24.683536"},{"key":"629_CR131","doi-asserted-by":"publisher","first-page":"e275","DOI":"10.1038\/cddis.2012.13","volume":"3","author":"W-Y Shi","year":"2012","unstructured":"Shi W-Y, Xiao D, Wang L, Dong L-H, Yan Z-X, Shen Z-X, et al. Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy. Cell Death Dis. 2012;3:e275\u2013e275. https:\/\/doi.org\/10.1038\/cddis.2012.13.","journal-title":"Cell Death Dis"},{"key":"629_CR132","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.celrep.2019.03.067","volume":"27","author":"D Vara-Ciruelos","year":"2019","unstructured":"Vara-Ciruelos D, Dandapani M, Russell FM, Grzes KM, Atrih A, Foretz M, et al. Phenformin, but not metformin, delays development of T cell acute lymphoblastic leukemia\/lymphoma via cell-autonomous AMPK activation. Cell Rep. 2019;27:690\u2013698.e4. https:\/\/doi.org\/10.1016\/j.celrep.2019.03.067.","journal-title":"Cell Rep"},{"key":"629_CR133","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.ccell.2016.12.003","volume":"31","author":"J Paul","year":"2017","unstructured":"Paul J, Soujon M, Wengner AM, Zitzmann-Kolbe S, Sturz A, Haike K, et al. Simultaneous inhibition of PI3K\u03b4 and PI3K\u03b1 induces ABC-DLBCL regression by blocking BCR-dependent and -independent activation of NF-\u03baB and AKT. Cancer Cell. 2017;31:64\u201378. https:\/\/doi.org\/10.1016\/j.ccell.2016.12.003.","journal-title":"Cancer Cell"},{"key":"629_CR134","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1038\/s41375-020-0743-y","volume":"34","author":"G Lenz","year":"2020","unstructured":"Lenz G, Hawkes E, Verhoef G, Haioun C, Thye Lim S, Seog Heo D, et al. Single-agent activity of phosphatidylinositol 3-kinase inhibition with copanlisib in patients with molecularly defined relapsed or refractory diffuse large B-cell lymphoma. Leukemia. 2020;34:2184\u201397. https:\/\/doi.org\/10.1038\/s41375-020-0743-y.","journal-title":"Leukemia"},{"key":"629_CR135","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1182\/blood-2018-08-872465","volume":"133","author":"K Bojarczuk","year":"2019","unstructured":"Bojarczuk K, Wienand K, Ryan JA, Chen L, Villalobos-Ortiz M, Mandato E, et al. Targeted inhibition of PI3K\u03b1\/\u03b4 is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL. Blood. 2019;133:70\u201380. https:\/\/doi.org\/10.1182\/blood-2018-08-872465.","journal-title":"Blood"},{"key":"629_CR136","doi-asserted-by":"publisher","first-page":"2718","DOI":"10.1200\/JCO.23.00033","volume":"41","author":"AJ Davies","year":"2023","unstructured":"Davies AJ, Barrans S, Stanton L, Caddy J, Wilding S, Saunders G, et al. Differential efficacy from the addition of bortezomib to R-CHOP in diffuse large B-cell lymphoma according to the molecular subgroup in the REMoDL-B study with a 5-year follow-up. J Clin Oncol. 2023;41:2718\u201323. https:\/\/doi.org\/10.1200\/JCO.23.00033.","journal-title":"J Clin Oncol"},{"key":"629_CR137","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","volume":"20","author":"A Davies","year":"2019","unstructured":"Davies A, Cummin TE, Barrans S, Maishman T, Mamot C, Novak U, et al. Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:649\u201362. https:\/\/doi.org\/10.1016\/S1470-2045(18)30935-5.","journal-title":"Lancet Oncol"},{"key":"629_CR138","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","volume":"113","author":"K Dunleavy","year":"2009","unstructured":"Dunleavy K, Pittaluga S, Czuczman MS, Dave SS, Wright G, Grant N, et al. Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood. 2009;113:6069\u201376. https:\/\/doi.org\/10.1182\/blood-2009-01-199679.","journal-title":"Blood"},{"key":"629_CR139","doi-asserted-by":"publisher","first-page":"5552","DOI":"10.3390\/cancers14225552","volume":"14","author":"K Kluckova","year":"2022","unstructured":"Kluckova K, D\u2019Avola A, Riches JC. Advances in understanding of metabolism of B-cell lymphoma: implications for therapy. Cancers. 2022;14:5552 https:\/\/doi.org\/10.3390\/cancers14225552.","journal-title":"Cancers"},{"key":"629_CR140","doi-asserted-by":"publisher","unstructured":"B\u00f6ttcher M, Baur R, Stoll A, Mackensen A, Mougiakakos D. Linking immunoevasion and metabolic reprogramming in B-cell\u2013derived lymphomas. Front Oncol. 2020;10. https:\/\/doi.org\/10.3389\/fonc.2020.594782.","DOI":"10.3389\/fonc.2020.594782"},{"key":"629_CR141","doi-asserted-by":"publisher","first-page":"11934","DOI":"10.1182\/blood-2022-166421","volume":"140","author":"Y Zhang","year":"2022","unstructured":"Zhang Y, Lv L, Wang C, Kong R, Lu T, Ding M, et al. Comprehensive metabolome analysis identified novel biomarkers for the diagnosis and prognosis of diffuse large B-cell lymphoma. Blood. 2022;140:11934\u20135. https:\/\/doi.org\/10.1182\/blood-2022-166421.","journal-title":"Blood"},{"key":"629_CR142","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025017248","author":"A Montagne","year":"2025","unstructured":"Montagne A, Bertho G, Papastergiou T, Chartier L, Ricci R, Jardin F, et al. Risk stratification of diffuse large B-cell lymphoma patients using plasma NMR-based metabolomics at diagnostic. Blood Adv. 2025. https:\/\/doi.org\/10.1182\/bloodadvances.2025017248.","journal-title":"Blood Adv"},{"key":"629_CR143","doi-asserted-by":"crossref","unstructured":"Lodhi N, Tun M, Nagpal P, Inamdar AA, Ayoub NM, Siyam N, et al. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine. Oncotarget. 2020;114045\u20134073.","DOI":"10.18632\/oncotarget.27785"}],"container-title":["Oncogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00629-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00629-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00629-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T19:59:02Z","timestamp":1778875142000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41389-026-00629-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":143,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["629"],"URL":"https:\/\/doi.org\/10.1038\/s41389-026-00629-x","relation":{},"ISSN":["2157-9024"],"issn-type":[{"value":"2157-9024","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]},"assertion":[{"value":"30 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 April 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22"}}